4 results
We propose a phase II study (intervention) in patients with severe generalized recessive dystrophic EB receiving reduced toxicity conditioning chemotherapy followe by cord blood transplantation with co-infusion of mesenchymal stromal cell units.…
To study the safety and feasibility of adding 6 weeks of orally administered Pazopanib to 25 x 2Gy in 5 weeks preoperative radiotherapy in soft tissue sarcoma patients (to identify the Dose Limiting Toxicity (DLT) and the Recommend Phase II Dose (…
To increase progression-free survival at 3 months.
Primary Objective:To investigate the proportion of patients with resection specimens demonstrating induction of a pathological (near) complete remission (* 95% tumor regression)Secondary Objectives:To study tumour changes to pre-operative pazopanib…